Patents by Inventor David Yaffe

David Yaffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically modified muscle cells which express neurotrophic factors
    Patent number: 10744162
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 18, 2020
    Assignees: RAMOT AT TEL-AVIV UNIVERSITY LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Daniel Offen, Michal Dadon-Nachum, Tali Ben-Zur, Eldad Melamed, David Yaffe
  • GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS
    Publication number: 20190201452
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 4, 2019
    Inventors: Daniel OFFEN, Michal DADON-NACHUM, Tali BEN-ZUR, Eldad MELAMED, David YAFFE
  • GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS
    Publication number: 20160279169
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Application
    Filed: June 13, 2016
    Publication date: September 29, 2016
    Applicants: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd.
    Inventors: Daniel OFFEN, Michal DADON-NACHUM, Tali BEN-ZUR, Eldad MELAMED, David YAFFE
  • Genetically modified muscle cells which express neurotrophic factors
    Patent number: 9365828
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: June 14, 2016
    Assignees: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co., Ltd.
    Inventors: Daniel Offen, Michal Dadon-Nachum, Tali Ben-Zur, Eldad Melamed, David Yaffe
  • GENETICALLY MODIFIED MUSCLE CELLS WHICH EXPRESS NEUROTROPHIC FACTORS
    Publication number: 20130344041
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Application
    Filed: March 1, 2012
    Publication date: December 26, 2013
    Applicants: Yeda Research and Development Co., Ltd., Ramot at Tel-Aviv University
    Inventors: Daniel Offen, Michal Dadon-Nachum, Tali Ben-Zur, Eldad Melamed, David Yaffe